Selected research
Industry Growth & Trends
Global Peptide CDMO Industry Growth and Trends Forecast to 2032
Market perspective
According to APO Research, the global Peptide CDMO market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The North America market for Peptide CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.
The Europe market for Peptide CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Peptide CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global companies in the Peptide CDMO market include Xinbang Pharma, ScinoPharm, SN Biopharm, Genscript, AmbioPharm, USV Peptides, Thermofischer, PolyPeptide and Piramal Pharma, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report provides a structured, data-driven view of the global Peptide CDMO market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The Peptide CDMO market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Peptide CDMO market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Peptide CDMO.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading companies in the global Peptide CDMO market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
Peptide CDMO Market by Company
Xinbang Pharma
ScinoPharm
SN Biopharm
Genscript
AmbioPharm
USV Peptides
Thermofischer
PolyPeptide
Piramal Pharma
JPT
CPC Scientific
CordenPharma
CBL
Bio Basic
Bachem
Peptide CDMO Segment by Type
APIs and Intermediates
FDF
Peptide CDMO Segment by Application
Commercial
Academic Research
Other
Peptide CDMO Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Peptide CDMO market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Peptide CDMO and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Peptide CDMO.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of Peptide CDMO companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- APIs and Intermediates
- FDF
Applications
- Commercial
- Academic Research
- Other
Companies covered
- Xinbang Pharma
- ScinoPharm
- SN Biopharm
- Genscript
- AmbioPharm
- USV Peptides
- Thermofischer
- PolyPeptide
- Piramal Pharma
- JPT
- CPC Scientific
- CordenPharma
- CBL
- Bio Basic
- Bachem
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global Peptide CDMO Market Size Overview by Region 2021 VS 2025 VS 2032
- 1.4 Global Peptide CDMO Market Size by Region (2021-2032)
- 1.4.1 Global Peptide CDMO Market Size by Region (2021-2026)
- 1.4.2 Global Peptide CDMO Market Size by Region (2027-2032)
- 1.5 Key Regions Peptide CDMO Market Size (2021-2032)
- 1.5.1 North America Peptide CDMO Market Size Growth Rate (2021-2032)
- 1.5.2 Europe Peptide CDMO Market Size Growth Rate (2021-2032)
- 1.5.3 Asia-Pacific Peptide CDMO Market Size Growth Rate (2021-2032)
- 1.5.4 South America Peptide CDMO Market Size Growth Rate (2021-2032)
- 1.5.5 Middle East & Africa Peptide CDMO Market Size Growth Rate (2021-2032)
2 Peptide CDMO Market by Type
- 2.1 Type Introduction
- 2.1.1 APIs and Intermediates
- 2.1.2 FDF
- 2.2 Global Peptide CDMO Market Size by Type
- 2.2.1 Global Peptide CDMO Market Size Overview by Type (2021-2032)
- 2.2.2 Global Peptide CDMO Historic Market Size Review by Type (2021-2026)
- 2.2.3 Global Peptide CDMO Market Size Forecasted by Type (2027-2032)
- 2.3 Global Peptide CDMO Market Size by Regions
- 2.3.1 North America Peptide CDMO Market Size Breakdown by Type (2021-2026)
- 2.3.2 Europe Peptide CDMO Market Size Breakdown by Type (2021-2026)
- 2.3.3 Asia-Pacific Peptide CDMO Market Size Breakdown by Type (2021-2026)
- 2.3.4 South America Peptide CDMO Market Size Breakdown by Type (2021-2026)
- 2.3.5 Middle East and Africa Peptide CDMO Market Size Breakdown by Type (2021-2026)
3 Peptide CDMO Market by Application
- 3.1 Type Introduction
- 3.1.1 Commercial
- 3.1.2 Academic Research
- 3.1.3 Other
- 3.2 Global Peptide CDMO Market Size by Application
- 3.2.1 Global Peptide CDMO Market Size Overview by Application (2021-2032)
- 3.2.2 Global Peptide CDMO Historic Market Size Review by Application (2021-2026)
- 3.2.3 Global Peptide CDMO Market Size Forecasted by Application (2027-2032)
- 3.3 Global Peptide CDMO Market Size by Regions
- 3.3.1 North America Peptide CDMO Market Size Breakdown by Application (2021-2026)
- 3.3.2 Europe Peptide CDMO Market Size Breakdown by Application (2021-2026)
- 3.3.3 Asia-Pacific Peptide CDMO Market Size Breakdown by Application (2021-2026)
- 3.3.4 South America Peptide CDMO Market Size Breakdown by Application (2021-2026)
- 3.3.5 Middle East and Africa Peptide CDMO Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
- 4.1 Peptide CDMO Industry Trends
- 4.2 Peptide CDMO Industry Drivers
- 4.3 Peptide CDMO Industry Opportunities and Challenges
- 4.4 Peptide CDMO Industry Restraints
5 Competitive Insights by Company
- 5.1 Global Top Players by Peptide CDMO Revenue (2021-2026)
- 5.2 Global Peptide CDMO Industry Company Ranking, 2024 VS 2025 VS 2026
- 5.3 Global Peptide CDMO Key Company Headquarters & Area Served
- 5.4 Global Peptide CDMO Company, Product Type & Application
- 5.5 Global Peptide CDMO Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global Peptide CDMO Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 Peptide CDMO Players Market Share by Revenue in 2025
- 5.6.3 2025 Peptide CDMO Tier 1, Tier 2, and Tier 3
6 Company Profiles
- 6.1 Xinbang Pharma
- 6.1.1 Xinbang Pharma Company Information
- 6.1.2 Xinbang Pharma Business Overview
- 6.1.3 Xinbang Pharma Peptide CDMO Revenue, Global Share and Gross Margin (2021-2026)
- 6.1.4 Xinbang Pharma Peptide CDMO Product Portfolio
- 6.1.5 Xinbang Pharma Recent Developments
- 6.2 ScinoPharm
- 6.2.1 ScinoPharm Company Information
- 6.2.2 ScinoPharm Business Overview
- 6.2.3 ScinoPharm Peptide CDMO Revenue, Global Share and Gross Margin (2021-2026)
- 6.2.4 ScinoPharm Peptide CDMO Product Portfolio
- 6.2.5 ScinoPharm Recent Developments
- 6.3 SN Biopharm
- 6.3.1 SN Biopharm Company Information
- 6.3.2 SN Biopharm Business Overview
- 6.3.3 SN Biopharm Peptide CDMO Revenue, Global Share and Gross Margin (2021-2026)
- 6.3.4 SN Biopharm Peptide CDMO Product Portfolio
- 6.3.5 SN Biopharm Recent Developments
- 6.4 Genscript
- 6.4.1 Genscript Company Information
- 6.4.2 Genscript Business Overview
- 6.4.3 Genscript Peptide CDMO Revenue, Global Share and Gross Margin (2021-2026)
- 6.4.4 Genscript Peptide CDMO Product Portfolio
- 6.4.5 Genscript Recent Developments
- 6.5 AmbioPharm
- 6.5.1 AmbioPharm Company Information
- 6.5.2 AmbioPharm Business Overview
- 6.5.3 AmbioPharm Peptide CDMO Revenue, Global Share and Gross Margin (2021-2026)
- 6.5.4 AmbioPharm Peptide CDMO Product Portfolio
- 6.5.5 AmbioPharm Recent Developments
- 6.6 USV Peptides
- 6.6.1 USV Peptides Company Information
- 6.6.2 USV Peptides Business Overview
- 6.6.3 USV Peptides Peptide CDMO Revenue, Global Share and Gross Margin (2021-2026)
- 6.6.4 USV Peptides Peptide CDMO Product Portfolio
- 6.6.5 USV Peptides Recent Developments
- 6.7 Thermofischer
- 6.7.1 Thermofischer Company Information
- 6.7.2 Thermofischer Business Overview
- 6.7.3 Thermofischer Peptide CDMO Revenue, Global Share and Gross Margin (2021-2026)
- 6.7.4 Thermofischer Peptide CDMO Product Portfolio
- 6.7.5 Thermofischer Recent Developments
- 6.8 PolyPeptide
- 6.8.1 PolyPeptide Company Information
- 6.8.2 PolyPeptide Business Overview
- 6.8.3 PolyPeptide Peptide CDMO Revenue, Global Share and Gross Margin (2021-2026)
- 6.8.4 PolyPeptide Peptide CDMO Product Portfolio
- 6.8.5 PolyPeptide Recent Developments
- 6.9 Piramal Pharma
- 6.9.1 Piramal Pharma Company Information
- 6.9.2 Piramal Pharma Business Overview
- 6.9.3 Piramal Pharma Peptide CDMO Revenue, Global Share and Gross Margin (2021-2026)
- 6.9.4 Piramal Pharma Peptide CDMO Product Portfolio
- 6.9.5 Piramal Pharma Recent Developments
- 6.10 JPT
- 6.10.1 JPT Company Information
- 6.10.2 JPT Business Overview
- 6.10.3 JPT Peptide CDMO Revenue, Global Share and Gross Margin (2021-2026)
- 6.10.4 JPT Peptide CDMO Product Portfolio
- 6.10.5 JPT Recent Developments
- 6.11 CPC Scientific
- 6.11.1 CPC Scientific Company Information
- 6.11.2 CPC Scientific Business Overview
- 6.11.3 CPC Scientific Peptide CDMO Revenue, Global Share and Gross Margin (2021-2026)
- 6.11.4 CPC Scientific Peptide CDMO Product Portfolio
- 6.11.5 CPC Scientific Recent Developments
- 6.12 CordenPharma
- 6.12.1 CordenPharma Company Information
- 6.12.2 CordenPharma Business Overview
- 6.12.3 CordenPharma Peptide CDMO Revenue, Global Share and Gross Margin (2021-2026)
- 6.12.4 CordenPharma Peptide CDMO Product Portfolio
- 6.12.5 CordenPharma Recent Developments
- 6.13 CBL
- 6.13.1 CBL Company Information
- 6.13.2 CBL Business Overview
- 6.13.3 CBL Peptide CDMO Revenue, Global Share and Gross Margin (2021-2026)
- 6.13.4 CBL Peptide CDMO Product Portfolio
- 6.13.5 CBL Recent Developments
- 6.14 Bio Basic
- 6.14.1 Bio Basic Company Information
- 6.14.2 Bio Basic Business Overview
- 6.14.3 Bio Basic Peptide CDMO Revenue, Global Share and Gross Margin (2021-2026)
- 6.14.4 Bio Basic Peptide CDMO Product Portfolio
- 6.14.5 Bio Basic Recent Developments
- 6.15 Bachem
- 6.15.1 Bachem Company Information
- 6.15.2 Bachem Business Overview
- 6.15.3 Bachem Peptide CDMO Revenue, Global Share and Gross Margin (2021-2026)
- 6.15.4 Bachem Peptide CDMO Product Portfolio
- 6.15.5 Bachem Recent Developments
7 North America
- 7.1 North America Peptide CDMO Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2 North America Peptide CDMO Market Size by Country (2021-2026)
- 7.3 North America Peptide CDMO Market Size Forecast by Country (2027-2032)
8 Europe
- 8.1 Europe Peptide CDMO Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2 Europe Peptide CDMO Market Size by Country (2021-2026)
- 8.3 Europe Peptide CDMO Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Peptide CDMO Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2 Asia-Pacific Peptide CDMO Market Size by Country (2021-2026)
- 9.3 Asia-Pacific Peptide CDMO Market Size Forecast by Country (2027-2032)
10 South America
- 10.1 South America Peptide CDMO Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2 South America Peptide CDMO Market Size by Country (2021-2026)
- 10.3 South America Peptide CDMO Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Peptide CDMO Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2 Middle East & Africa Peptide CDMO Market Size by Country (2021-2026)
- 11.3 Middle East & Africa Peptide CDMO Market Size Forecast by Country (2027-2032)
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst